Mandi led growth in FY22E, NRDL renewal de-risked
FY22 Preview: Strong execution of “3+3 Strategy”; Raise TP to HK$2.66
FY22业绩符合预期,温和复苏可期
华润医药:1H22业绩巩固了FY22E的正面
FY22预计稳中向好,疫情无碍新财年起航,品牌韧性历经考验
石四药集团:强劲的1H22结果;但FY22E指引略低
FY22销售成绩优异,核心产品加速渗透目标市场
知乎(ZH US)4Q21E 稳健,FY22E 过渡
Positive profit alert for FY22; eyeing for a good FY23E
FY22 largely in-line; Auto/VR to accelerate growth